In our study we found that: 1) c-myc is amplified in 19% of hepatocellular carcinoma at FISH molecular level, whereas show gains in 55% and set wild in 26% of respectively cases; 2) at clinical level, c-myc gene amplification is significantly correlated with DFS and OS in patients with HCC after surgical resection and identifies patients with risk of early relapse (≤12 months). This evidence concerns the gene MYC and hepatocellular carcinoma.